Judge Grants Final Approval Of $688M Settlement In 2 Securities Class Actions

Judge Grants Final Approval Of $688M Settlement In 2 Securities Class Actions

NEWARK, N.J. - A federal judge in New Jersey on Oct. 1 granted final approval of a $688 million settlement in two securities class action lawsuits alleging that Merck and Co. Inc. and others failed to disclose adverse results of a clinical trial for two cholesterol drugs Merck was developing (In Re: Merck & Co., Vytorin/Zetia Securities Litigation, No. 2:08-CV-2177, D. N.J.; In Re: Schering-Plough Corp./ENHANCE Securities Litigation, 08-397, D. N.J.).

Find full version on lexis Advance®
Access this news story on lexis.com®